Reported Earlier, Immutep Teams Up With MSD To Test Efti And KEYTRUDA Combination In Phase III Non-Small Cell Lung Cancer Trial
Portfolio Pulse from Benzinga Newsdesk
Immutep has partnered with MSD to test a combination of efti and KEYTRUDA in a Phase III trial for first-line non-small cell lung cancer (1L NSCLC). The trial will enroll approximately 750 patients and aims to address the entire 1L NSCLC market eligible for anti-PD-1 therapy. Immutep will conduct the trial, while MSD will supply KEYTRUDA. Immutep retains commercial rights to efti.
June 03, 2024 | 5:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep's partnership with MSD to test efti and KEYTRUDA in a Phase III trial for 1L NSCLC could significantly impact its stock. The trial's success could open up a large market for Immutep's efti.
The collaboration with MSD and the initiation of a Phase III trial for a significant cancer indication (1L NSCLC) is a major milestone for Immutep. Positive trial results could lead to significant commercial opportunities for efti.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
MSD (Merck & Co.) will supply KEYTRUDA for the Phase III trial with Immutep. This collaboration could further solidify KEYTRUDA's position in the 1L NSCLC market.
By supplying KEYTRUDA for the trial, MSD could strengthen its market position in the 1L NSCLC segment. Successful trial results could lead to increased usage of KEYTRUDA in combination therapies.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70